Physician profile
Ernesto Alonso
NPI 1396170601
$211,134.96
in general payments reported to CMS, 2019-2025
69 companies · $20K in 2025
The $20K reported for 2025 was more than what 91% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $1,977 · 2021: $58K · 2022: $63K · 2023: $36K · 2024: $32K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $13K · Honoraria: $8,500 · Travel and Lodging: $3,068 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,250.00 |
| Food and Beverage | $13,056.93 |
| Honoraria | $8,500.00 |
| Travel and Lodging | $3,068.04 |
| Education | $116.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175,507.54 | 2021-2025 | Ubrelvy, Qulipta |
| Axsome Therapeutics, INC. | $9,674.20 | 2025 | Symbravo, Auvelity, Sunosi |
| Allergan, INC. | $4,052.11 | 2020-2021 | |
| Lundbeck LLC | $2,239.65 | 2019-2025 | Vyepti, Rexulti |
| Ipsen Innovation | $1,850.66 | 2024 | |
| Lilly USA, LLC | $1,124.00 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $1,101.85 | 2019-2025 | |
| Amgen INC. | $1,068.64 | 2019-2025 | Uplizna |
| Biogen, INC. | $938.70 | 2020-2025 | Tysabri, Vumerity, Skyclarys |
| Eisai INC. | $910.10 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $835.85 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $762.85 | 2020-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $688.76 | 2021-2025 | Ultomiris |
| Pfizer INC. | $583.65 | 2022-2025 | |
| Genentech USA, INC. | $501.71 | 2020-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $484.60 | 2021-2024 | |
| Ucb, INC. | $469.28 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Argenx US, INC. | $452.39 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Harmony Biosciences LLC | $450.12 | 2020-2025 | |
| Kyowa Kirin, INC. | $416.90 | 2022-2025 | Nourianz |
| Tanabe Pharma America, INC. | $386.24 | 2019-2024 | |
| Mdd US Operations, LLC | $385.57 | 2020-2025 | Gocovri |
| Emd Serono, INC. | $380.63 | 2020-2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $359.40 | 2022-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $342.78 | 2022-2025 | Crexont, Rytary |
| Abbott Laboratories | $333.20 | 2021-2024 | Jot Dx |
| Csl Behring | $324.68 | 2023-2025 | Hizentra |
| Supernus Pharmaceuticals, INC. | $298.17 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $295.62 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $288.57 | 2019-2025 | Nuplazid |
| Corium, LLC | $269.92 | 2022-2023 | Adlarity |
| Alnylam Pharmaceuticals INC. | $262.01 | 2021-2024 | Onpattro |
| Celgene Corporation | $242.35 | 2022-2025 | Zeposia |
| Adamas Pharmaceuticals, INC. | $240.08 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $231.34 | 2022-2023 | Trudhesa |
| Neurelis, INC. | $200.85 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $156.49 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $152.53 | 2023-2025 | Ingrezza, Ongentys |
| Greenwich Biosciences, INC. | $142.48 | 2019-2021 | |
| Janssen Biotech, INC. | $109.62 | 2025 | |
| Merz Pharmaceuticals, LLC | $109.17 | 2025 | Xeomin, Inbrija |
| Octapharma USA, INC. | $102.33 | 2023-2024 | Panzyga |
| Tg Therapeutics, INC. | $101.70 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $101.38 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.48 | 2021 | |
| Grifols USA, LLC | $85.32 | 2022-2023 | Gamunex-C |
| Inspire Medical Systems, INC. | $85.26 | 2023-2024 | Inspire |
| Genzyme Corporation | $80.69 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $78.71 | 2025 | Wainua |
| Grt US Holding, INC. | $67.07 | 2022 | |
| Boston Scientific Corporation | $65.95 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $63.29 | 2022 | |
| Averitas Pharma INC. | $62.14 | 2024-2025 | Qutenza |
| Strongbridge US INC. | $60.82 | 2020 | |
| Janssen Pharmaceuticals, INC | $56.45 | 2022-2023 | Spravato |
| Livanova USA, INC. | $52.71 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $49.66 | 2024-2025 | Hyqvia |
| Scilex Pharmaceuticals INC. | $42.68 | 2022-2024 | |
| Akcea Therapeutics, INC. | $40.11 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $33.82 | 2023 | Fycompa |
| Assertio Therapeutics, INC. | $33.60 | 2019 | |
| Zyla Life Sciences, INC. | $32.43 | 2020 | |
| Acorda Therapeutics, INC | $23.45 | 2022 | |
| Life Molecular Imaging Ltd | $21.74 | 2025 | Neuraceq |
| Microtransponder, INC. | $21.26 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.62 | 2021 | |
| Cycle Pharmaceuticals INC | $14.14 | 2025 | Tascenso Odt |
| C2n Diagnostics, LLC | $13.47 | 2025 | Precivityad2 |
| Avanir Pharmaceuticals, INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.